Population
Patients with chronic heart failure (CHF)
Design
Review
Authors
Loading...
Reinforces polypharmacy for chronic HF outcomes; leaves open biomarker-guided personalization in future trials.
A historical and forward-looking review of heart failure pharmacotherapy emphasizing the shift towards polypharmacy and the future need for personalized biomarkers.
J. N. Cohn (2000) studied this question.